Patients with oropharyngeal cancer and discordant p16 and HPV molecular testing results (p16-/HPV+ (3.8%) or p16+/HPV- (5.6%)) have a significantly worse prognosis than patients with p16+/HPV + oropharyngeal cancer but better than patients with p16-/HPV- oropharyngeal cancer [27]. Here, CDKN2A is linked to oropharynx cancer.